|
Edward Roberts contributes extensive experience in the development of drugs to treat disorders of the central nervous system, which he has studied both in the pharmaceutical industry at Hoffmann-La Roche, Astra (now AstraZeneca), and the Parke-Davis Neuroscience Research Centre at Addenbrookes Hospital and in academia. He currently serves as Professor of Translational Chemistry and Medicine at the Scripps Research Institute, and he previously served as Chief Scientific Officer of biotechnology company Kemia, which specializes in small molecule kinase inhibitors. Roberts was also previously senior Vice President and Head of Discovery Chemistry for F. Hoffmann-La Roche in Basel. He has served on governmental committees and was a Professor at Montreal's McGill University. He is currently a Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry. An author and inventor on numerous original scientific articles and patents, Roberts earned his Ph.D. in Synthetic Organic Chemistry from the University of Newcastle Upon Tyne and his B.Sc. in Biochemistry from the University of Sussex, both in England. | 